Clinical Convergence: A Patient-Centered Approach to Child and Adolescent Bipolar Depression
To access this course and earn 1.0 contact hours, click the View Course button below. This is an enduring symposia offering originally presented at the APNA 34th Annual Conference.
Clinical Convergence® A Patient-Centered Approach to Child and Adolescent Bipolar Depression
Product not yet rated Contains 4 Component(s)Presenters: Sara Jones, PhD, RN, APRN, PMHNP-BC, Robert A. Kowatch, MD, PhD 1.0 contact hours
-
Register
- Non-member - Free!
- Regular Member - Free!
- Retired Member - Free!
- Affiliate Member - Free!
- Student Member - Free!
- More Information
-
Register
Antipsychotics in Practice: The When, Why, and How of Using LAIs
To access this course and earn 1.0 contact hours, click the View Course button below and register for an account. This is an enduring symposia offering originally presented at the APNA 34th Annual Conference.
Learning Objectives: After completing this educational activity, you should be better able to:
- Identify patients who may benefit from transition to a long-acting injectable antispsychotic (LAI)
- Differentiate the pharmacology and clinical profiles of LAIs
- Facilitate a smooth transition when converting from oral to LAIs
Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.
Released: September 30, 2020 NCPD credit expires: September 30, 2023
Achieving and Maintaining Improved Quality of Life in Patients with Tardive Dyskinesia
To access this course and earn 1.0 contact hours, click the View Course button below. This is an enduring symposia offering originally presented at the APNA 34th Annual Conference.
Learning Objectives: After completing this educational activity, you should be better able to:
- Outline the consequences of untreated TD on QoL in patients taking antipsychotic medications
- Describe the clinical indications for and clinical benefits of administering the AIMS exam
- Incorporate currently available data on the long-term efficacy and safety of VMAT2 inhibitors for the treatment of TD into clinical practice
Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences and Teva Pharmaceuticals.
Released: September 2020 NCPD Credit Expires: November 9, 2021
Access Date | Quiz Result | Score | Actions |
---|